Recombinant Rat 4-1BB Ligand / TNFSF9 Protein, His,Flag Tag (MALS verified), 100 µg

Background
Tumor necrosis factor ligand superfamily member 9 (4-1BBL) is also known as 4-1BB ligand, CD137L or TNFSF9, which is a cytokine that binds to TNFRSF9. 4-1BBL is the high affinity ligand of 4-1BB. 4-1BBL induces the proliferation of activated peripheral blood T-cells. Also, 4-1BBL may have a role in activation-induced cell death (AICD). Furthermore, 4-1BBL may play a role in cognate interactions between T-cells and B-cells/macrophages. As for diseases, 4-1BBL is involved in cancers, infectious diseases and autoimmune diseases.

Source
Recombinant Rat 4-1BB Ligand His,Flag Tag (41L-R52D3) is expressed from human 293 cells (HEK293). It contains AA Pro 106 - Gly 308 (Accession # Q80WE6-1).
Predicted N-terminus: His

Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus, followed by a flag tag.
The protein has a calculated MW of 72.3 kDa. The protein migrates as 95-115 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma"
Yuti, Sawasdee, Natungnuy et al
Biomed Pharmacother (2023) 168, 115691
(2) "Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands"
Garman, Jiang, Daouti et al
Front Immunol (2023) 14, 1151748
(3) "Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists"
Fromm, de Silva, Schreiber
Front Immunol (2023) 14, 1236332
Showing 1-3 of 765 papers.